miR-122 An Exploratory Biomarker of Liver Injury: An Industry Perspective on the State of the Science and Experiences Pre-Clinically and Clinically

The Critical Path Institute’s Predictive Safety Testing Consortium (PSTC) hosted a webinar focused on providing an industry perspective on the state of the science and preclinical and clinical experiences with miR122. This webinar was hosted by PSTC’s Hepatotoxicity Working Group.

The first presentation discussed the current state of miR-122 as a safety biomarker of liver injury and highlighted recent work on miR-122 in exosomes during early hepatic injury. The following presentations provided a pharmaceutical industry perspective on the utility of miR-122 in preclinical and clinical studies. Rodent data generated by AbbVie demonstrated the utility of miR-122 in preclinical studies. Additionally, speakers from Pfizer and Genentech discussed human data generated in healthy volunteers and patient populations, the difficulties facing use of miR-122 in the clinic, and how miR signatures may add value to the evaluation of liver injury and liver disease.

Organizers: Kathila Rajapaksa, Genentech; Rachel Church, UNC; Tatiana Sharapova, AbbVie; Shelli Schomaker, Pfizer; William Proctor, Genentech; and Jennifer Burkey, Critical Path Institute

The webinar was held on May 2, 2017. The webinar is available here to the public.

Webinar Recording

Presentations

<table>
<thead>
<tr>
<th>Presentation Title and Presenter</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 1 miR-122: More Than Just Your Average Leakage Biomarker  
*Rachel Church (University of North Carolina)* | Image not found or type unknown |
| 2 Evaluation of miR-122 as a Serum Biomarker for Hepatotoxicity in Investigative Rat Toxicology Studies  
*Tatiana Sharapova (AbbVie, Inc.)* | Image not found or type unknown |
| 3 Emerging Biomarkers of Liver Injury: from miR-122 to Liquid Biopsies  
*Shelli Schomaker (Pfizer, Inc.)* | Image not found or type unknown |
| 4 Variability of Circulating miR-122 in Human Serum  
*Will Proctor (Genentech, Inc.)* | Image not found or type unknown |